Cizzle Bio, Inc.

09/16/2026

Tonight, Cizzle Bio is honored to support the Prevent Cancer Foundation’s 2026 Annual Gala at the National Building Museum in Washington, D.C.

We are proud to contribute a Bronze-Level pledge and to have Founder and CEO Bill Behnke serve on the Gala Committee in support of the Foundation’s cancer prevention and early detection mission.

Cizzle Bio’s UK partner, Cizzle Biotechnology, and its CEO, Allan Syms, will also be attending alongside Cizzle Bio and Bill Behnke.

Learn more:
https://go.cizzlebio.com/fZXHbw

09/14/2026

Cizzle Bio is proud to support the Prevent Cancer Foundation’s 2026 Annual Gala on September 16 in Washington, D.C.

With a Bronze-Level pledge, a table at the event, and Founder and CEO Bill Behnke serving on the Gala Committee, we are honored to support programs that advance cancer prevention and early detection.

Read more about Cizzle Bio’s support for the Gala: https://go.cizzlebio.com/KBwwYZ

09/08/2026

Join us for a live conversation on blood cancer.

Our own Berkley Behnke, Director of Communications at Cizzle Bio, Inc., and Ella Behnke, a Non-Hodgkin's Lymphoblastic Lymphoma survivor, will be part of "Blood Cancer Uncovered: Answers, Treatment and Support" — a new TikTok Live series from GLOW-Oncology (Global Leadership in Oncology & Wellness) alongside Blood Cancer United (formerly The Leukemia & Lymphoma Society).

September 16, 2026 at 7 PM ET
Watch live in the TikTok app at

Follow on TikTok to tune in.

09/04/2026

The CIZ1B Biomarker Blood Test is designed to complement LDCT and other standard diagnostic approaches.

It may provide clinicians with an additional biomarker-based tool as part of a comprehensive lung cancer assessment.

Healthcare providers can review ordering setup steps here:
https://go.cizzlebio.com/Kqc4W3

09/01/2026

New peer-reviewed research published in The Journal of Applied Laboratory Medicine supports the clinical utility of the CIZ1B biomarker for early lung cancer detection.

The study — led by Professor Dawn Coverley of the University of York — evaluated the same ELISA-based assay now commercially available to licensed healthcare providers in Dallas-Fort Worth and San Antonio. In the early-stage cohort, CIZ1B demonstrated 94% sensitivity and a 97% negative predictive value.

Read the press release: https://go.cizzlebio.com/5aPGDU

08/29/2026

The CIZ1B Biomarker Blood Test for Lung Cancer may provide licensed healthcare providers with an additional biomarker-based tool during lung cancer assessment.

Review clinician resources and ordering setup steps:
https://go.cizzlebio.com/pqkko2

08/27/2026

Cizzle Bio attended the Next Generation DX Summit 2026 in Washington, DC, where Dr. Lary Robinson of Moffitt Cancer Center presented on the potential of the CIZ1B biomarker to redefine early lung cancer detection.

Our post-event recap shares key takeaways from the presentation, including discussion of blood-based biomarkers, LDCT screening challenges, indeterminate pulmonary nodules, and the Moffitt Cancer Center clinical study evaluating CIZ1B.

Read the recap:
https://buff.ly/VvZc39w

Cizzle Bio recaps Dr. Lary Robinson’s Next Generation DX Summit 2026 presentation on CIZ1B, blood-based biomarkers, lung nodules, LDCT screening, and early lung cancer detection.

08/27/2026

Licensed healthcare providers can access CIZ1B Biomarker Blood Test clinician resources, including clinical information, patient considerations, and ordering setup steps.

Provider resources:
https://buff.ly/cMtGzCi

08/27/2026

Cizzle Bio was proud to participate in the 18th Annual Next Generation Dx Summit in Washington, DC.

Dr. Lary A. Robinson, director of the Lung Cancer Early Detection (LEAD) Center at Moffitt Cancer Center, presented "Potential of the CIZ1B Biomarker to Redefine Early Lung Cancer Detection" — examining how blood-based biomarkers may help clinicians evaluate indeterminate lung nodules and support earlier detection.

The CIZ1B Biomarker Blood Test is now available through licensed healthcare providers in Dallas-Fort Worth and San Antonio.

Read the full announcement: https://buff.ly/tMMQDb7

/PRNewswire/ -- Cizzle Bio Inc., a biotechnology company advancing biomarker blood tests for early cancer detection, today announced its participation in the...

08/25/2026

We were proud to attend the Next Generation DX Summit 2026 in Washington, D.C.

One of the highlights was a presentation by Dr. Lary Robinson, Director of the Lung Cancer Early Detection Center (LEAD) at Moffitt Cancer Center, on the potential of the CIZ1B biomarker blood test for early lung cancer detection.

Dr. Robinson also discussed the clinical validation study of the CIZ1B biomarker blood test currently underway at Moffitt Cancer Center.

It was wonderful to see Dr. Robinson and Cizzle Bio CEO Bill Behnke together following the presentation.

Detect Early. Save Lives.